New combo attack on tough liver cancer shows promise in Real-World study
NCT ID NCT07272265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 300 adults with high-risk liver cancer who received a combination of two drugs (atezolizumab and bevacizumab) plus chemotherapy infused directly into the liver artery. The goal was to see how well this treatment worked and how safe it was in everyday medical practice. The study is already completed, and researchers are analyzing survival and tumor progression data from medical records across 10 hospitals in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs) plus liver artery infusion of FOLFOX chemotherapy
What this could lead to
If successful, this combination could offer a more effective first-line treatment option for patients with high-risk liver cancer that has spread to major blood vessels or bile ducts.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be less reliable. The combination also carries risks of serious side effects from both immunotherapy and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China